CTMX CytomX Therapeutics, Inc.

NASDAQ
$1.98

CytomX Therapeutics, Inc. (CTMX) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.6% since its last earnings release on November 5, 2026.

CytomX Therapeutics Reported In-line with Estimates
Thursday, November 5, 2026 · 4:15 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($0.10)
Rev est $4.24M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.02

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.